Cadence Pharmaceuticals, Inc. (CADX) Misses Q1 EPS by 5c; Guides Q2 Sales Below
Tweet
Share
E-mailGet Alerts CADX Hot Sheet
Price: $13.98 --0%
Financial Fact:
Cost of product sales: 11.55M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Cost of product sales: 11.55M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) reported Q1 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $8 million versus the consensus estimate of $8.93 million.
Sees Q2 2012 revenue of $10-$10.4 million, versus the consensus of $15.0 million.
For earnings history and earnings-related data on Cadence Pharmaceuticals, Inc. (CADX) click here.
Sees Q2 2012 revenue of $10-$10.4 million, versus the consensus of $15.0 million.
For earnings history and earnings-related data on Cadence Pharmaceuticals, Inc. (CADX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c
- Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
